Endothelial Cell‐Specific Molecule‐1 (ESM1): An Endogenous Anticoagulant and Protective Factor in Venous Thrombosis
Advanced Science · 2026
DOI: 10.1002/advs.202515994 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Changsheng Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China. Hauptthemen laut MEDLINE: Venous Thrombosis, Proteoglycans, Neoplasm Proteins, Anticoagulants. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Deficiencies in endogenous anticoagulation pathways can lead to vascular occlusion and thrombosis. Endothelial cell‐specific molecule‐1 (ESM1), a proteoglycan secreted by endothelial cells, is elevated in patients with venous thromboembolism (VTE), yet its role in coagulation regulation remains undefined. Serum ESM1 concentrations are significantly higher in individuals with VTE (498.54 pg/mL) than in healthy controls (198.68 pg/mL), and the combination of ESM1 and D‐dimer increases diagnostic discrimination. The anticoagulant potential of ESM1 is assessed using time‐to‐occlusion (TTO) assays in zebrafish and mouse models, complemented by in vitro analyses of endogenous thrombin inhibitor activation. The anticoagulant effect of recombinant human ESM1 was further examined in mouse model. Loss of esm1 in zebrafish results in vascular occlusion in the cardinal vein, whereas esm1 overexpression dose‐dependently reduces venous thrombosis and prolongs TTO. Similarly, Esm1 knockout in mice leads to an alteration of coagulation function, which is rescued by human ESM1 protein. Mechanistically, ESM1's anticoagulant function is found to rely on its covalently linked glycosaminoglycans (GAGs), which activate the thrombin inhibitor heparin cofactor II (HCII). This study uncovers a novel function of ESM1 in anticoagulation through HCII activation, highlighting its potential as a therapeutic target for preventing venous thrombus formation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China.
- Department of Interventional and Vascular Surgery, Affiliated Hospital of Nantong University, Nantong, China.
- Nantong Science and Technology College, Nantong, China.
- Institute of Special Environmental Medicine, Nantong University, Nantong, China.
- Medical College of Nantong University, Nantong, China.
- State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center For Translational Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai,…
ORCID-Profile: Dong Liu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, C., Ge, X., Fu, D., Mei, H., Lv, F., Yang, C., Lu, J., Shen, X., Li, B., Wang, X., & Liu, D. (2026). Endothelial Cell‐Specific Molecule‐1 (ESM1): An Endogenous Anticoagulant and Protective Factor in Venous Thrombosis. Advanced Science. https://doi.org/10.1002/advs.202515994
Vancouver
Chen C, Ge X, Fu D, Mei H, Lv F, Yang C, et al. Endothelial Cell‐Specific Molecule‐1 (ESM1): An Endogenous Anticoagulant and Protective Factor in Venous Thrombosis. Advanced Science. 2026. doi:10.1002/advs.202515994
BibTeX
@article{Chen2026,
author = {Chen, Changsheng and Ge, Xiaojuan and Fu, Dongxu and Mei, Haijun and Lv, Feng and Yang, Chao and Lu, Jiahao and Shen, Xiaozhong and Li, Bowen and Wang, Xiaoning and Liu, Dong},
title = {Endothelial Cell‐Specific Molecule‐1 (ESM1): An Endogenous Anticoagulant and Protective Factor in Venous Thrombosis},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202515994}
}
EUVIMED